About us

Broken String Biosciences is building a technology platform that accelerates the characterisation of novel genome editing technologies. This will unlock the next wave of cell & gene therapies.

Our vision is a future where cell & gene therapies are safer, more efficient, and affordable for patients. Starting with our DNA break mapping technology INDUCE-seq™, our data-driven platform reveals precisely how genome editors interact with and alter our genomes. This information is essential for the efficient development of novel genome editing systems and will unlock many new targets within the genome for therapeutic development.

Broken String Biosciences is backed by Illumina and Tencent and is based at the Wellcome Genome Campus, Cambridge, UK.



INDUCE-seq™ is a game changing technology for the characterisation of genome breaks in cell & gene therapy applications.

Read more about INDUCE-seq™ in Nature Communications

Get in touch to find out more about how INDUCE-seq™ can empower your cell & gene therapy development process.


We are building partnerships with scientific leaders and world-renowned organisations.

Integrated DNA Technologies
UK Regenerative Medicine Platform

Interested in joining our team?

Come and join our dynamic and growing team to share in our vision of delivering on the promise of gene editing


All News

  • Test post

    Test post

    Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Donec odio. Quisque volutpat mattis eros. Nullam malesuada erat ut turpis. Suspendisse urna nibh viverra non semper suscipit posuere a pede. Donec nec justo eget felis facilisis fermentum. Aliquam porttitor mauris sit amet orci. Aenean dignissim pellentesque felis. Morbi in sem quis dui placerat ornare. Pellentesque odio…

    Read more

  • Broken String Biosciences joins Campus

    Broken String Biosciences joins Campus

    Cell & gene therapies based on genome editing technologies such as CRISPR-Cas9 are positioned to become a new generation of transformative therapeutics, with the ability to correct disease at the genetic level. Because they directly alter our DNA and have the propensity to go ‘off-target’, assessing whether these therapies are safe for patients is extremely…

    Read more

  • Genomics company Broken String Biosciences expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park

    Genomics company Broken String Biosciences expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park

    Chesterford Research Park is delighted to welcome Broken String Biosciences to the Park’s eminent Science Village. Aiming to develop safer cell and gene therapies by assessing the stability of the genome, Broken String Biosciences is leveraging novel genomic sequencing approaches to build a technology platform that will drive the development of CRISPR cell and gene therapies that…

    Read more